^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    GENE:

    HLA-DRB5 (Major Histocompatibility Complex, Class II, DR Beta 5)

    i
    Other names: HLA-DRB5, Major Histocompatibility Complex, Class II, DR Beta 5, MHC Class II Antigen DRB5, DR Beta-5, HLA Class II Histocompatibility Antigen, DR-5 Beta Chain, HLA Class II Histocompatibility Antigen, DR Beta 5 Chain, DR2-Beta-2, HLA-DRB5*, DRB5, Dw2
    24d
    Molecular profiling of breast cancer in native American women reveals distinct genomic and transcriptomic features. (PubMed, NPJ Precis Oncol)
    We also noted contrasts in nucleotide-excision-repair involvement (ERCC5/POLE mutations vs ERCC1/CUL4A CNV gains), and mutational-signature analysis indicated greater MMR- and AID/POLE-associated exposures in the White cohort. To our knowledge, this study provides an initial multi-omics characterization of breast tumors from Native American women and offers a resource and hypotheses for larger, harmonized studies to assess prognostic and therapeutic relevance.
    Journal • BRCA Biomarker
    |
    PD-L1 (Programmed death ligand 1) • POLE (DNA Polymerase Epsilon) • ERCC1 (Excision repair cross-complementation group 1) • BRCA (Breast cancer early onset) • HLA-DRB1 (Major Histocompatibility Complex, Class II, DR Beta 1) • ARID1B (AT-Rich Interaction Domain 1B) • CUL4A (Cullin 4A) • NOTCH4 (Notch 4) • ERCC5 (ERCC Excision Repair 5 Endonuclease 2) • HLA-B (Major Histocompatibility Complex, Class I, B) • HLA-DRB5 (Major Histocompatibility Complex, Class II, DR Beta 5)
    |
    POLE mutation
    1m
    Single-cell transcriptomic profiling combined with Mendelian randomization illuminates molecular drivers of bladder cancer. (PubMed, Mol Genet Genomics)
    In vitro experiments demonstrated that ARHGEF18 knockdown and YPEL5 overexpression led to decreased cell proliferation, migration, invasion, and increased apoptosis in T24 and 5637 bladder cancer cells. Our findings identify ARHGEF18 and YPEL5 as genetically and transcriptionally supported regulators of bladder cancer, highlighting a scalable strategy for linking genetic risk to cell-type-specific mechanisms.
    Journal
    |
    HLA-DRB5 (Major Histocompatibility Complex, Class II, DR Beta 5) • ISG20 (Interferon Stimulated Exonuclease Gene 20)
    3ms
    Integrating single-cell and bulk transcriptomes identifies B cell features associated with neoadjuvant chemoradiotherapy sensitivity in rectal cancer. (PubMed, Sci Rep)
    This study reveals that a B cell subpopulation characterized by the co-expression of HLA-DRB5, HLA-DQA2, HLA-DQB1, CD74, and ACTG1 is significantly associated with nCRT response in rectal cancer. These findings offer actionable insights for optimizing clinical treatment strategies, including patient stratification and personalized therapy selection.
    Journal • PD(L)-1 Biomarker • IO biomarker
    |
    PD-L1 (Programmed death ligand 1) • CD74 (CD74 Molecule) • HLA-DQB1 (Major Histocompatibility Complex, Class II, DQ Beta 1) • HLA-DRB5 (Major Histocompatibility Complex, Class II, DR Beta 5) • ACTG1 (Actin Gamma 1)
    |
    PD-L1 expression
    7ms
    Transcriptome-wide Mendelian randomization exploring dynamic CD4+ T cell gene expression in colorectal cancer development. (PubMed, J Leukoc Biol)
    However, many of genetic proxies used to instrument gene expression in CD4+ T cells also act as eQTLs in other tissues, highlighting the challenges of using genetic proxies to instrument tissue-specific expression changes. We demonstrate the importance of capturing the dynamic nature of CD4+ T cells in understanding CRC risk, and prioritize genes for further investigation in cancer prevention.
    Journal
    |
    HLA-DRB1 (Major Histocompatibility Complex, Class II, DR Beta 1) • CD4 (CD4 Molecule) • HLA-DRB5 (Major Histocompatibility Complex, Class II, DR Beta 5) • UNC13D (Unc-13 Homolog D) • FADS2 (Fatty Acid Desaturase 2)
    8ms
    Spatial deciphering of the transcriptomic heterogeneity of tumor spread through air spaces in lung cancer. (PubMed, Front Pharmacol)
    These results were validated in an independent cohort by multiplex immunofluorescence stainings. This study is the first to use DSP to analyze spatial transcriptomic profiles of NSCLC tumor nests and air space tumors, and it identifies potential module features that may be used for STAS identification and prognosis.
    Journal
    |
    CD4 (CD4 Molecule) • HLA-DRB5 (Major Histocompatibility Complex, Class II, DR Beta 5) • RASGRF1 (Ras Protein Specific Guanine Nucleotide Releasing Factor 1) • ITGA2 (Integrin Subunit Alpha 2)
    9ms
    High-Resolution Genotyping of HLA Alleles and Association with Genetic Background of Virological Response in Chronic Hepatitis B. (PubMed, Clin Lab)
    Integrating next-generation sequencing data of HLA genes in genomic and epigenomic data can offer a comprehensive understanding of the molecular mechanisms underlying HBV infection. This integrated approach will help identify new biomarkers, deeply understand the complex interactions between genetic and epigenetic factors, and facilitate the development of personalized prevention and treatment strategies.
    Journal
    |
    HLA-DRB1 (Major Histocompatibility Complex, Class II, DR Beta 1) • HLA-DQB1 (Major Histocompatibility Complex, Class II, DQ Beta 1) • HLA-B (Major Histocompatibility Complex, Class I, B) • HLA-DQA1 (Major Histocompatibility Complex, Class II, DQ Alpha 1) • HLA-DRB5 (Major Histocompatibility Complex, Class II, DR Beta 5) • HLA-C (Major Histocompatibility Complex, Class I, C)
    11ms
    Integration of transcriptome-wide association study and gene-based association analysis identifies candidate genes for Hodgkin lymphoma. (PubMed, J Cancer Res Clin Oncol)
    These findings highlight the role of the exogenous antigen presentation pathway in HL, shedding light on potential mechanisms.
    Journal
    |
    HLA-DRB1 (Major Histocompatibility Complex, Class II, DR Beta 1) • HLA-DQB1 (Major Histocompatibility Complex, Class II, DQ Beta 1) • NOTCH4 (Notch 4) • HLA-DPB1 (Major Histocompatibility Complex, Class II, DP Beta 1) • HLA-DQA1 (Major Histocompatibility Complex, Class II, DQ Alpha 1) • HLA-DRB5 (Major Histocompatibility Complex, Class II, DR Beta 5)
    11ms
    The cancer stem cells characteristics analysis of LGR5 + cells that influence lung cancer risk by using single cell RNA-seq analysis. (PubMed, Sci Rep)
    In addition, the marker genes of three CSCs were also overexpressed in LUAD cells and the CXCL3 played an important role in mediating cell proliferation, apoptosis, migration and invasion of tumor. We performed a scRNA-seq analysis and identified the LGR5 + stem cell as a major contributor in LUAD progression, our findings are expected to provide new insights into the pathogenesis of LUAD.
    Journal
    |
    CD74 (CD74 Molecule) • HLA-DPB1 (Major Histocompatibility Complex, Class II, DP Beta 1) • HLA-DRB5 (Major Histocompatibility Complex, Class II, DR Beta 5) • CXCL3 (C-X-C Motif Chemokine Ligand 3)
    11ms
    Transcriptome-wide Mendelian randomisation exploring dynamic CD4+ T cell gene expression in colorectal cancer development. (PubMed, medRxiv)
    However, our sensitivity analysis revealed that the genetic proxies used to instrument gene expression in CD4+ T cells also act as eQTLs in other tissues, highlighting the challenges of using genetic proxies to instrument tissue-specific expression changes. Our study demonstrates the importance of capturing the dynamic nature of CD4+ T cells in understanding disease risk, and prioritises genes for further investigation in cancer prevention research.
    Journal
    |
    HLA-DRB1 (Major Histocompatibility Complex, Class II, DR Beta 1) • CD4 (CD4 Molecule) • HLA-DRB5 (Major Histocompatibility Complex, Class II, DR Beta 5) • UNC13D (Unc-13 Homolog D) • FADS2 (Fatty Acid Desaturase 2)
    12ms
    Development and validation of a disulfidptosis-related genes signature for predicting outcomes and immunotherapy in acute myeloid leukemia. (PubMed, Front Immunol)
    Knockdown of PTPN6 and CSK inhibited the proliferation of AML cells and increased apoptosis. Our study provides insights into DRG prognoses and immunomodulation, establishing a robust 6-gene risk model for predicting AML outcomes that may enhance precision medicine and treatment strategies.
    Journal • IO biomarker
    |
    IFNG (Interferon, gamma) • HLA-DRB5 (Major Histocompatibility Complex, Class II, DR Beta 5)
    12ms
    Unveiling hypoxia-related prognostic and immunotherapeutic biomarkers in lung adenocarcinoma through single-cell and bulk RNA sequencing: Including insights into PGF. (PubMed, Int J Biol Macromol)
    The experimental results confirmed that hypoxia-related genes play a significant role in driving LUAD progression. In conclusion, our study provides valuable insights into the hypoxic and immunosuppressive tumor microenvironment, which serve as a potential prognostic marker and therapeutic target for LUAD.
    Journal • PD(L)-1 Biomarker • IO biomarker
    |
    HLA-DRB5 (Major Histocompatibility Complex, Class II, DR Beta 5) • TIMP3 (TIMP Metallopeptidase Inhibitor 3) • S100B (S100 Calcium Binding Protein B)